Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial

Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial

- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 - - Preliminary Phase 1 data demonstrated rapid, deep, and sustained effects on key biomarkers for at least 8...

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®. Sofdra is the first and only FDA-approved new chemical entity...

MS Pharma Announces Strategic Growth Investment from Olayan Financing Company

MS Pharma Announces Strategic Growth Investment from Olayan Financing Company

Strategic Partnership to Accelerate Growth in Saudi Arabia and Across the MENA Region AMMAN, Jordan and RIYADH, Saudi Arabia, May 18, 2026 /PRNewswire/ -- MS Pharma today announced that Olayan Financing Company (OFC) has made a minority equity...

TOYO Co., Ltd Announces Unaudited and Unreviewed First Quarter 2026 Financial Results and Reaffirms Guidance

TOYO Co., Ltd Announces Unaudited and Unreviewed First Quarter 2026 Financial Results and Reaffirms Guidance

TOKYO, May 18, 2026 /PRNewswire/ -- TOYO Co., Ltd (Nasdaq: TOYO) (OTC: TOYWF), ("TOYO" or the "Company"), a solar solution company, today announced its unaudited and unreviewed financial results for the first quarter ended March 31, 2026, and...

Earendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

Earendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

WILMINGTON, Del., May 18, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced the successful completion of cohort 1 dosing in a phase I clinical trial...

Baidu Announces First Quarter 2026 Results

Baidu Announces First Quarter 2026 Results

BEIJING, May 18, 2026 /PRNewswire/ -- Baidu, Inc. (NASDAQ: BIDU and HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)), ("Baidu" or the "Company"), a leading AI company with strong Internet foundation, today announced its unaudited financial results...

Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

Hu-mAtrIx™-Enabled Next-Generation ACVR2A/2B- Targeting Antibody Demonstrates Potential to Become a Best-in-Class Therapy for Obesity CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, May 18, 2026 /PRNewswire/ -- Harbour BioMed (the "Company";...

JX Luxventure Group Inc. Announces Fiscal Year 2025 Financial Results: Revenue Surges 66% to $83.0 Million

JX Luxventure Group Inc. Announces Fiscal Year 2025 Financial Results: Revenue Surges 66% to $83.0 Million

HAIKOU, China, May 15, 2026 /PRNewswire/ -- JX Luxventure Group Inc. (Nasdaq: JXG) (the "Company"), a company in the wholesale trade sector specializing in duty-free and cross-border consumer goods, as well as providing integrated solutions in...

Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial

Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial

Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced solid tumor patients SYDNEY, May 15, 2026 /PRNewswire/ -- Racura Oncology, an Australian Phase 3...

EZGO Announces 1-for-150 Reverse Share Split Effective May 19, 2026

EZGO Announces 1-for-150 Reverse Share Split Effective May 19, 2026

CHANGZHOU, China, May 15, 2026 /PRNewswire/ -- EZGO Technologies Ltd. (Nasdaq: EZGO) ("EZGO" or "we," "our," or the "Company"), a leading short-distance transportation solutions provider in China, today announced that on May 6, 2026, its board of...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 66
  • menu
    menu